MedWatch

Novo Nordisk upgrades guidance for the rest of the year

The day before the publication of Novo Nordisk's Q2 report, the company has upgraded its guidance for 2021. Figures from the quarterly report show a positive surprise on the pharmaceutical company's top and bottom lines.

Photo: Tidsvilde Stine/Ritzau Scanpix

Already on Wednesday afternoon, Denmark's largest pharmaceutical company, Novo Nordisk, has disclosed the figures for the second quarter of the year, while the company also upgrades its guidance for the firm's revenue and operating result.

Now, Novo Nordisk expects revenue growth in the range of 10-13 percent after currency adjustments, up against the previous 6-10 percent. As to the operating profit, the firm predicts this will grow between 9-12 percent after currency adjustments, compared with the previous 5-9 percent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs